Article
Body mass index and nutritional intake following Elexacaftor/Tezacaftor/Ivacaftor modulator therapy in adults with cystic fibrosis.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society - 1 Nov 2023
Caley L R, Jarosz-Griffiths H H, Smith L, Gale L, Barrett J, Kinsey L, Davey V, Nash M, Jones A M, Whitehouse J L, Shimmin D, Floto R A, White H, Peckham D G
Abstract excerpt
BACKGROUND: Elexacaftor/Tezacaftor/Ivacaftor (ETI) modulator therapy is often associated with increased body mass index (BMI) in people with cystic fibrosis (CF). This is thought to reflect improved clinical stability and increased appetite and nutritional intake. We explored the change in BMI and nutritional intake following ETI modulator therapy in adults with CF. METHODS: Dietary intake, measured with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.